Biologic Basis of Disparity in Liver Cancer Survival Among Asian Americans

亚裔美国人肝癌生存差异的生物学基础

基本信息

项目摘要

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is a blatant example of a cancer health disparity in that HCC is disproportionally higher in incidence and mortality among Asian Americans compared with non-Hispanic Whites. Infection by the Hepatitis B virus (HBV) is the principal risk factor for HCC among Asian Americans. HCC survival rates have significantly improved among those whose cancer is detected early and treated aggressively, but remain short among those with advanced, and rapidly progressive disease. Thus elucidating biological mechanisms underlying the behavior of HBV-mediated HCC will potentially contribute to improved surveillance, treatment, control and prevention. Our long term goal is to understand epidemiologic causes, sociocultural barriers, and biologic mechanisms of HBV-related disparities, and to develop tools which can decrease the burden of these diseases on the Asian American community. In this study, we will compare viral factors and immune responses in HBV-infected Laotian and Hmong, who experience the highest HCC mortality rates among Asians, with HBV-infected Chinese and Vietnamese, who experience better survival rates. Importantly, Laotian and Hmong are also diagnosed at a younger age but with more advanced disease compared to other Asian ethnicities suggesting that there is a biologic basis to this disparity in HCC survival. Our central hypothesis is that differences in viral variants and host immune responses exist within the Laotian/Hmong population, which in part cause an earlier onset and more aggressive form of HCC, resulting in a disparity in HCC survival. We propose using next generation sequencing technologies to 1) compare viral factors associated with HCC prognosis in HBV-infected Laotian/Hmong to HBV-infected Chinese and Vietnamese and 2) assess immune responses associated with HCC survival in these same groups by gene expression activity of pro-inflammatory responses including NF?B-related genes and anti-inflammatory responses such as regulatory T cells, as well as T cell receptor usage and HLA allele frequencies. The impact of this study will be to improve the understanding of the biologic basis of disparities in HCC survival among Asian American ethnicities and may lead to better risk stratification and tailoring of treatment of HCC based upon host and viral factors.
描述(由申请人提供):肝细胞癌(HCC)是癌症健康差异的一个明显例子,因为与非西班牙裔白人相比,亚裔美国人的HCC发病率和死亡率不成比例地高。B肝炎病毒(HBV)感染是亚裔美国人肝癌的主要危险因素。在早期发现癌症并积极治疗的患者中,HCC生存率显着提高,但在晚期和快速进展的疾病患者中仍然很短。因此,阐明HBV介导的HCC行为的生物学机制将有助于改善监测、治疗、控制和预防。我们的长期目标是了解HBV相关差异的流行病学原因,社会文化障碍和生物学机制,并开发可以减少这些疾病对亚裔美国人社区负担的工具。在这项研究中,我们将比较HBV感染的老挝人和苗族人的病毒因素和免疫反应,他们在亚洲人中经历了最高的HCC死亡率,HBV感染的中国人和越南人,他们经历了更好的生存率。重要的是,老挝人和苗族人也在较年轻的年龄被诊断出肝癌,但与其他亚洲种族相比,他们的病情更严重,这表明肝癌生存率的这种差异有生物学基础。我们的中心假设是,病毒变异和宿主免疫反应的差异存在于老挝/苗族人群中,这在一定程度上导致了HCC的早期发病和更具侵袭性的形式,导致HCC生存率的差异。我们建议使用下一代测序技术1)比较HBV感染的老挝/苗族人与HBV感染的中国人和越南人中与HCC预后相关的病毒因素,2)通过促炎反应的基因表达活性(包括NF?B相关基因和抗炎反应,如调节性T细胞,以及T细胞受体的使用和HLA等位基因频率。这项研究的影响将是提高对亚裔美国人肝癌生存差异的生物学基础的理解,并可能导致更好的风险分层和基于宿主和病毒因素的肝癌治疗的定制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER L. BOWLUS其他文献

CHRISTOPHER L. BOWLUS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER L. BOWLUS', 18)}}的其他基金

SACRAMENTO COLLABORATIVE TO ADVANCE TESTING AND CARE OF HEPATITIS B (SCRATCH)
萨克拉门托合作推进乙型肝炎(划痕)检测和护理
  • 批准号:
    8876888
  • 财政年份:
    2014
  • 资助金额:
    $ 19.71万
  • 项目类别:
SACRAMENTO COLLABORATIVE TO ADVANCE TESTING AND CARE OF HEPATITIS B (SCRATCH)
萨克拉门托合作推进乙型肝炎(划痕)检测和护理
  • 批准号:
    8919153
  • 财政年份:
    2014
  • 资助金额:
    $ 19.71万
  • 项目类别:
Biologic Basis of Disparity in Liver Cancer Survival Among Asian Americans
亚裔美国人肝癌生存差异的生物学基础
  • 批准号:
    8585383
  • 财政年份:
    2013
  • 资助金额:
    $ 19.71万
  • 项目类别:
Oxidative mutagenesis:Iron, Ascorbic Acid and Genes
氧化诱变:铁、抗坏血酸和基因
  • 批准号:
    6524846
  • 财政年份:
    2001
  • 资助金额:
    $ 19.71万
  • 项目类别:
Oxidative mutagenesis:Iron, Ascorbic Acid and Genes
氧化诱变:铁、抗坏血酸和基因
  • 批准号:
    6447620
  • 财政年份:
    2001
  • 资助金额:
    $ 19.71万
  • 项目类别:
CLONING OF THE HEMOCHROMATOSIS LOCUS
血色素沉着症基因座的克隆
  • 批准号:
    2733811
  • 财政年份:
    1998
  • 资助金额:
    $ 19.71万
  • 项目类别:
CLONING OF THE HEMOCHROMATOSIS LOCUS
血色素沉着症基因座的克隆
  • 批准号:
    6176841
  • 财政年份:
    1996
  • 资助金额:
    $ 19.71万
  • 项目类别:
CLONING OF THE HEMOCHROMATOSIS LOCUS
血色素沉着症基因座的克隆
  • 批准号:
    2134343
  • 财政年份:
    1996
  • 资助金额:
    $ 19.71万
  • 项目类别:
CLONING OF THE HEMOCHROMATOSIS LOCUS
血色素沉着症基因座的克隆
  • 批准号:
    2904939
  • 财政年份:
    1996
  • 资助金额:
    $ 19.71万
  • 项目类别:
CLONING OF THE HEMOCHROMATOSIS LOCUS
血色素沉着症基因座的克隆
  • 批准号:
    2823216
  • 财政年份:
    1996
  • 资助金额:
    $ 19.71万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 19.71万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 19.71万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 19.71万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 19.71万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 19.71万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 19.71万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 19.71万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 19.71万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 19.71万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 19.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了